| Expression pattern: |
UP |
| Associated gene: |
EIF4A3, IGF2BP2, LDHA mRNA, c-Myc mRNA, c-Myc protein |
| Associated microRNA: |
- |
| Biological function: |
Promotes docetaxel resistance, tumor growth, cell proliferation, aerobic glycolysis, glucose consumption, lactate production, and LDH activity in prostate cancer cells. |
| Molecular mechanism: |
EIF4A3 induces circARHGAP29 cyclization and cytoplasmic export; circARHGAP29 binds IGF2BP2 to stabilize LDHA mRNA and also stabilizes c-Myc mRNA and protein, thereby increasing LDHA transcription and promoting glycolytic metabolism. |
| Biological pathway or process: |
glycolysis (promotes); drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); mRNA stability (promotes); other pathway/process (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; ChIP / ChIP-seq; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
Elevated circARHGAP29 was associated with higher Gleason grade, advanced clinical tumor stages, and worse response to docetaxel therapy; it was proposed as a prognostic biomarker and therapeutic target in chemoresistant prostate cancer. |
| Description: |
circARHGAP29 is an ARHGAP29-derived human circRNA that is upregulated in prostate cancer, especially docetaxel-resistant PCa cells and clinical samples. EIF4A3 promotes its biogenesis and cytoplasmic export, while circARHGAP29 enhances docetaxel resistance and aerobic glycolysis by interacting with IGF2BP2, stabilizing LDHA mRNA, and stabilizing c-Myc mRNA/protein to increase LDHA transcription. Clinically, elevated circARHGAP29 is associated with higher Gleason grade, advanced tumor stage, and poorer response to docetaxel therapy. |
| Confidence score: |
0.886 |